Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED BALANCE SHEETS

v2.4.0.6
CONSOLIDATED BALANCE SHEETS (USD $)
Mar. 31, 2013
Dec. 31, 2012
ASSETS    
Cash    $ 782
Due from Triumph Capital      
Prepaid expenses      
Total current assets    782
Fixed assets - net 1,813 1,496
Patents & Trademarks 1,000   
Total Assets 2,813 2,278
LIABILITIES & STOCKHOLDERS' EQUITY    
Accounts payable 333,497 298,994
Accrued interest payable 179,455 159,355
Notes payable - current - related parties 390,915 390,915
Notes payable - current 634,789 225,136
Note discount (51,804) (38,072)
Notes payable - equity obligation payable 555,796 463,037
Stock subscription payable - current 26,000 26,000
Related party payables 303,632 351,310
Other payables 83,006 158,006
Total current liabilities 2,455,286 2,034,681
Notes payable - related parties 167,007 363,888
Total Liabilities 2,622,293 2,398,569
Stockholders' Equity    
Common stock, $.00001 par value; 100,000,000 shares authorized; 31,290,149 and 30,315,554 shares issued and outstanding at March 31, 2013 and December 31, 2012 respectively 313 303
Additional paid in capital 12,120,770 11,903,279
Deficit accumulated during the development stage (14,712,719) (14,274,244)
Total TransBiotec, Inc. stockholders' equity (2,591,636) (2,370,662)
Noncontrolling interest (27,844) (25,629)
Total Stockholders' Equity (2,619,480) (2,396,291)
Total Liabilities and Stockholders' Equity $ 2,813 $ 2,278